Articles
🇺🇸 AmericasExpert insights, opinion pieces, and in-depth analysis on pharmaceutical trends and FDA regulations.
Opinion: Lawmakers promised cancer patients would be protected from Medicaid cuts. Now CMS says otherwise
A new CMS interim final rule on Medicaid work requirements could force cancer patients, including those in active treatment, to meet work hours as a condition of coverage, contradicting earlier legislative promises. This development has significant implications for patient access to oncology therapies and for pharmaceutical market access strategies.
Utah Medical Board Scolded for Going Rogue with AI Criticism: Deal Implications for Pharma
The Utah Medical Board was publicly scolded for its rogue criticism of Doctronic's AI prescribing pilot. This analysis breaks down the regulatory clash, implications for pharma deal teams, and what to watch next.
SGS Expands Bioanalytical Testing Capabilities in North America with Acquisition of CMIC, INC.
SGS has acquired CMIC, INC., a Chicago-based bioanalytical testing firm, expanding its North American capabilities. The move follows the Keystone Bioanalytical acquisition and signals SGS's commitment to end-to-end drug development lifecycle testing.
ASCO26: Gastrointestinal Cancers Enter the Limelight Amid Key Readout Surge
ASCO 2026 is set to feature a surge of key readouts in gastrointestinal cancers, including hepatocellular carcinoma, pancreatic, gastric, and salivary gland cancers. This article provides a competitive benchmarking analysis for pharma strategy and business development teams.
Mercury Acquires King Courier to Grow Bay Area Logistics: Deal Intelligence for Pharma Teams
Mercury, a global healthcare and life sciences logistics provider, has acquired King Courier, a San Francisco-based logistics company serving Northern California for decades. The deal expands Mercury's operations in one of the nation's largest biotech and healthcare hubs.
Best Biotech News Sources: How Legend Biotech Emerged as a Rare Market Winner
Legend Biotech shares soared over 40% after disclosing early in vivo CAR-T data in Non-Hodgkin's lymphoma. This analysis explains the development, implications for pharma teams, and key milestones to track.
Genstar-backed Signant Health Acquires Ametris: Implications for eCOA and Digital Outcome Measures
Signant Health, backed by Genstar Capital, has acquired Ametris (formerly ActiGraph) from Archimed, creating an integrated platform for electronic clinical outcome assessments (eCOA) and wearable-derived digital measures. The deal consolidates two key clinical trial technology providers, with implications for study design, data quality, and vendor consolidation.
FDA Concerns About Cancer Risk Sink Fulcrum Therapeutics’ Sickle Cell Disease Drug: Implications for SCD Pipeline and BD Strategy
Fulcrum Therapeutics is discontinuing its lead sickle cell disease drug, pociredir, after the FDA raised concerns about cancer risk. The decision, which sent shares down 52%, reshapes the SCD competitive landscape and opens strategic questions for pipeline watchers and BD teams.
Antibody-Drug Conjugates in Lung Cancer: The Tip of the Iceberg
Antibody-drug conjugates (ADCs) represent a novel class of therapeutics that selectively target tumor cells and deliver concentrated cytotoxic payloads, showing significant antitumor activity in lung cancer. This analysis covers the latest evidence, key targets, and strategic implications for BD teams, investors, and analysts.
Abivax Ulcerative Colitis Drug Shows Strong Efficacy, But Cases of Cancer Raise Concerns
Abivax's obefazimod achieved a 40% placebo-adjusted clinical remission rate in a phase 3 ulcerative colitis trial, but several high-dose patients developed cancers, causing a stock collapse. This analysis examines the efficacy-safety trade-off and implications for pharma deal-making.
Kailera's Triple-G Drug: A Potential Game-Changer in Pharma
Kailera's triple-G drug showed powerful efficacy in early trials announced May 27, 2026. This catalyst analysis outlines implications for pharma business development, regulatory teams, and investors.
FDA's Future: Insights from Former Commissioner David Kessler
Former FDA Commissioner David Kessler, speaking at the STAT Breakthrough Summit West on May 19, 2026, expressed cautious optimism about the agency's ability to thrive despite recent high-profile departures and internal turmoil. This analysis distills his insights and outlines implications for pharmaceutical business development and regulatory strategy teams.
Bio-IT World Conference 2026: Live Event Coverage
Live coverage of the Bio-IT World Conference 2026 in Boston, highlighting key announcements, partnership trends, and regulatory implications for pharma BD and strategy teams.
FDA Shakeup: Høeg's Departure and Amgen Drug Controversy
The FDA's dismissal of acting CDER director Tracy Høeg and the revelation of 20 patient deaths linked to Amgen's Tavneos in Japan create a dual crisis of regulatory leadership and drug safety. This analysis provides key takeaways, a timeline of events, and strategic implications for pharmaceutical BD and regulatory teams.
BioMarin Rare Disease Therapy Fails Phase 3: Key Takeaways for Pharma Teams
BioMarin Pharmaceutical's rare disease therapy failed to show clinical benefit in a Phase 3 trial, triggering a reassessment of R&D strategy and investor confidence. This article covers key takeaways, regulatory implications, and actionable insights for pharma business development and regulatory teams.
Biotech's Strategic Turning Point: Insights from Jeremy Levin
Jeremy Levin discusses the biotech industry's strategic turning point, highlighting key developments and their implications for pharmaceutical teams. The analysis underscores the imperative for pharma to embrace strategic partnerships and foster innovation to maintain a competitive edge.
Kenya Court Halts U.S. Ebola Quarantine Facility Plans: Pharma Sector Analysis
A Kenyan High Court has suspended a U.S. plan to build an Ebola quarantine facility for Americans, raising new risks for pharma companies operating in Africa. The decision highlights the need for stronger local regulatory engagement and community-focused access strategies.
ASCO Preview: Akeso's Ivonescimab Under Scrutiny
As Akeso prepares for a plenary presentation at ASCO 2026, ivonescimab's HARMONi-6 overall survival data will be closely watched. This article covers key takeaways, competitive implications, and next milestones for pharma teams and investors.
Drug Discovery USA 2026: What to Expect
Drug Discovery USA 2026 in Cambridge, MA, will spotlight breakthrough drug launches and regulatory updates. This analysis covers key takeaways, implications for pharma teams, and answers to top industry questions.
Pfizer sharpens prostate cancer case with Talzenna win — oncology
Pfizer announced a Phase III win for Talzenna (talazoparib) plus Xtandi (enzalutamide) in metastatic castration-sensitive prostate cancer, setting up a potential broader label. This analysis covers the TALAPRO-3 results, implications for the prostate cancer treatment landscape, and key milestones for pharma teams and investors.